Get started
Author

Claire Roberts

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
2018 · Orrin Devinsky, Anup D. Patel, et al. · New England Journal of Medicine · 1,012
PDF
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
2018 · Elizabeth A Thiele, Eric D Marsh, et al. · The Lancet · 903
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
2022 · Michael S. Rafii, Reisa A. Sperling, et al. · Alzheimer s & Dementia · 289
PDF
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
2018 · Orrin Devinsky, Rima Nabbout, et al. · Epilepsia · 271
PDF
Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
2019 · Elizabeth Thiele, Eric Marsh, et al. · Epilepsia · 143
PDF
Species‐specific susceptibility to cannabis‐induced convulsions
2018 · Benjamin J Whalley, Hong Lin, et al. · British Journal of Pharmacology · 52
PDF
Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)
2017 · Jacqueline French, Elizabeth Thiele, et al. · Neurology · 23
Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5) (S19.003)
2018 · Ian Miller, Orrin Devinsky, et al. · Neurology · 6
IP 110. Maintenance of Long-Term Safety and Efficacy of Cannabidiol Treatment in Dravet’s Syndrome: Results of an Open-Label Extension Trial (GWPCARE5)
2018 · Orrin Devinsky, Rima Nabbout, et al. · Neuropediatrics · 3
Exposure-Response Analysis of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox–Gastaut Syndrome (P1.271)
2018 · Gilmour Morrison, Maria Luisa Sardu, et al. · Neurology · 3
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression
2026 · Claire Roberts, Mathieu Seynaeve, et al. · Journal of Psychopharmacology · 2
Amyloid burden assessed by three amyloid PET tracers in the elenbecestat MissionAD Phase 3 program
2020 · Claire Roberts, June Kaplow, et al. · Alzheimer s & Dementia · 2
PDF
Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results from Open-label Extension Trial (GWPCARE5) (P1.264)
2018 · Jonathan Halford, Eric Marsh, et al. · Neurology · 2
AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid
2021 · Jin Zhou, Michael C Irizarry, et al. · Alzheimer s & Dementia · 1
P1‐041: Apoe4 Status and Amyloid Burden Differences Across Regions in the Elenbecestat Missionad Phase 3 Program
2019 · Claire Roberts, Michio Kanekiyo, et al. · Alzheimer s & Dementia · 1
Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5) (P5.5-001)
2019 · Anup Patel, Antonio Gil-Nagel, et al. · Neurology
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
2018 · Wilson, Richard, Dass, P. Hari, et al. · Research Portal (Queen's University Belfast)
IP 112. Cannabidiol Treatment Effect and Adverse Events in Patients with Lennox–Gastaut’s syndrome: Pooled Results from Two Trials
2018 · Antonio Gil-Nagel, Michael Privitera, et al. · Neuropediatrics
Works count: 18
Citation count: 2,713
H-index: 7
I10-index: 7
Year
Topic
Type